Celgene

This early-stage study aimed to find the best dose and check the safety of combining alnuctamab and mezigdomide for people with multiple myeloma that had come back or stopped responding to treatment. Only 4 participants were enrolled before the study was stopped early. The main g…

This study tested a new drug, CC-92480, alone or with dexamethasone, in 200 people with multiple myeloma that returned after at least three prior treatments. The goal was to check safety, dosing, and how well it worked. The trial was terminated early, so results are limited.

This study tested whether the oral drug ozanimod could keep Crohn's disease under control in people with moderate-to-severe symptoms. About 550 participants who had already responded to an initial treatment were randomly assigned to receive ozanimod or a placebo for up to 52 week…

This study tested a cell therapy called bb2121 (Ide-cel) combined with other drugs in 21 adults with multiple myeloma that had returned or stopped responding to treatment. The goal was to find the safest dose and see if the combinations helped control the cancer. The trial was te…

This study tested an oral medication called ozanimod to help people with moderate-to-severe Crohn's disease reach remission (fewer symptoms). About 625 adults with Crohn's who had not responded well to other treatments were randomly assigned to receive ozanimod or a placebo for 1…

This study looked at the long-term safety and effectiveness of the oral drug ozanimod for people with moderate to severe Crohn's disease. It was an extension study for participants who completed earlier studies. The study was terminated early, so results are limited.

This study was a registry that followed over 3,000 adults newly diagnosed with multiple myeloma to understand how the disease is managed in everyday medical practice. Researchers collected information on patient backgrounds, treatments, and outcomes without providing any new ther…